S*BIO’s SB1317 enters Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies
S*BIO’s SB1317 enters Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies
S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO’s oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO’s development and commercialization partner for the program …
Read more on News-Medical-Net
Categories: Breast Cancer Treatment Tags: advanced/refractory, Clinical, Enters, hematologic, malignancies, Patients, Phase, S*BIO's, SB1317, Trial
Eisai enters strategic drug discovery collaboration with FORMA Therapeutics
Eisai enters strategic drug discovery collaboration with FORMA Therapeutics
Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., and FORMA Therapeutics announced today that the two companies have signed a strategic drug discovery collaboration.
Read more on News-Medical-Net
Categories: Breast Cancer Pain Tags: collaboration, Discovery, drug, Eisai, Enters, FORMA, strategic, Therapeutics'
Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
TUSTIN, CA–(Marketwire – 07/13/10) – Radient Pharmaceuticals Corporation (RPC) (AMEX: RPC – News ) announced today that it has entered into a letter of intent (LOI) to acquire Provista Diagnostics Inc. (PDI), a Nevada corporation offering laboratory testing services that meet the Clinical Laboratory Improvement Act (CLIA) guidelines. Radient Pharmaceuticals intends to acquire PDI, in a stock …
Read more on Marketwire via Yahoo! Finance
Categories: Breast Cancer Risks Tags: Acquire, diagnostics, Enters, Inc., Intent, into, Letter, Pharmaceuticals, Provista, Radient
Shionogi Enters into Exclusive License Agreement with QuatRx Pharmaceuticals to Market Ospemifene
Shionogi Enters into Exclusive License Agreement with QuatRx Pharmaceuticals to Market Ospemifene
OSAKA, Japan—-Shionogi & Co., Ltd. and QuatRx Pharmaceuticals Company , a privately-held pharmaceutical company, today announced that they have entered into a worldwide license agreement to develop and market ospemifene, a selective estrogen receptor modulator .
Read more on Business Wire via Yahoo! Finance
Categories: Breast Cancer Symptoms Tags: Agreement, Enters, Exclusive, into, License, Market, Ospemifene, Pharmaceuticals, QuatRx, Shionogi